

TDMs No. 99024 - 08

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 05/09/2008

Test Type: CHRONIC

Androstenedione

Time Report Requested: 12:55:58

Route: GAVAGE

CAS Number: 63-05-8

First Dose M/F: 12/16/02 / 12/16/02

Species/Strain: MICE/B6C3F1

Lab: SRI

F1_M3

C Number: C99024C

Lock Date: 06/29/2006

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

Study Gender: Both

TDMSE Version: 2.0.0

Test Type: CHRONIC

Androstenedione

Time Report Requested: 12:55:58

Route: GAVAGE

CAS Number: 63-05-8

First Dose M/F: 12/16/02 / 12/16/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	5	2	5	3
Natural Death	9	4	11	10
Survivors				
Terminal Sacrifice	36	44	34	37
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Gallbladder	(45)	(46)	(42)	(44)
Epithelium, Cytoplasmic Alteration		1 [3.0]		
Intestine Large, Cecum	(50)	(49)	(50)	(49)
Edema	1 [2.0]	1 [2.0]	1 [2.0]	
Intestine Small, Duodenum	(47)	(49)	(46)	(49)
Intestine Small, Ileum	(49)	(50)	(49)	(49)
Hyperplasia, Lymphoid	1 [3.0]			
Intestine Small, Jejunum	(47)	(49)	(47)	(49)
Hyperplasia, Lymphoid	1 [3.0]		1 [2.0]	1 [3.0]
Epithelium, Hyperplasia		1 [1.0]		
Liver	(50)	(50)	(50)	(50)
Angiectasis			1 [2.0]	
Basophilic Focus	1	2	1	1
Clear Cell Focus	27	24	18	12
Cyst	1 [3.0]			2 [3.0]
Eosinophilic Focus	13	10	11	25
Hematopoietic Cell Proliferation		1 [4.0]	4 [2.0]	
Hemorrhage	1 [2.0]	1 [1.0]		1 [2.0]
Infiltration Cellular			2 [2.5]	
Infiltration Cellular, Mixed Cell	1 [2.0]	1 [1.0]	5 [2.2]	2 [2.5]
Mitotic Alteration			1 [2.0]	
Mixed Cell Focus	10	10	11	13
Necrosis				1 [3.0]
Necrosis, Focal	3 [3.0]	3 [2.7]	5 [2.8]	6 [2.0]
Tension Lipidosis				1
Vacuolization Cytoplasmic	1 [1.0]	1 [2.0]	1 [2.0]	1 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Androstenedione

Time Report Requested: 12:55:58

Route: GAVAGE

CAS Number: 63-05-8

First Dose M/F: 12/16/02 / 12/16/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Centrilobular, Necrosis	2 [3.0]		3 [3.3]	4 [2.8]
Hepatocyte, Vacuolization Cytoplasmic	17 [2.9]	14 [2.9]	14 [2.7]	12 [3.1]
Kupffer Cell, Hyperplasia	1 [2.0]		1 [2.0]	
Mesentery	(5)	(8)	(4)	(5)
Hemorrhage	2 [2.5]			
Fat, Necrosis	4 [2.3]	7 [2.6]	2 [3.5]	4 [3.0]
Pancreas	(50)	(50)	(50)	(49)
Atrophy	1 [2.0]	2 [1.0]		
Thrombosis				1 [4.0]
Acinus, Cytoplasmic Alteration	1 [3.0]	3 [2.0]	2 [3.0]	
Acinus, Hyperplasia, Focal	1 [2.0]			
Salivary Glands	(50)	(50)	(50)	(50)
Atrophy	1 [1.0]			1 [1.0]
Infiltration Cellular, Lymphocyte	2 [2.5]	4 [2.3]	3 [2.0]	6 [2.5]
Stomach, Forestomach	(49)	(50)	(50)	(50)
Edema				1 [2.0]
Erosion	1 [1.0]			
Inflammation, Chronic		1 [3.0]		1 [2.0]
Ulcer	1 [2.0]	1 [3.0]	1 [3.0]	
Epithelium, Hyperplasia	1 [1.0]	5 [2.2]	1 [2.0]	2 [1.5]
Stomach, Glandular	(49)	(50)	(50)	(50)
Edema			1 [2.0]	
Erosion			2 [1.5]	1 [2.0]
Epithelium, Hyperplasia	1 [3.0]	2 [2.0]		
Epithelium, Hyperplasia, Focal	1 [2.0]			
Tooth	(0)	(1)	(0)	(0)
CARDIOVASCULAR SYSTEM				
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	4 [1.5]	4 [1.0]	5 [1.0]	7 [1.1]
Hemorrhage				1 [2.0]
Inflammation, Chronic			1 [3.0]	
Mineralization			1 [4.0]	
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(49)	(50)	(50)
Accessory Adrenal Cortical Nodule	6 [3.0]	1 [3.0]	3 [3.0]	2 [3.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Androstenedione

Time Report Requested: 12:55:58

Route: GAVAGE

CAS Number: 63-05-8

First Dose M/F: 12/16/02 / 12/16/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Hyperplasia, Focal	4 [2.3]	5 [1.8]	5 [2.0]	3 [1.3]
Hypertrophy, Focal	10 [1.5]	7 [1.3]	11 [1.5]	9 [1.8]
Metaplasia, Osseous	1 [3.0]			
Capsule, Hyperplasia	5 [2.6]	4 [2.3]	5 [2.2]	10 [2.3]
Adrenal Medulla	(49)	(49)	(50)	(50)
Hyperplasia			1 [1.0]	
Islets, Pancreatic	(50)	(50)	(50)	(49)
Hyperplasia	12 [2.3]	14 [2.5]	11 [2.3]	6 [2.0]
Parathyroid Gland	(48)	(48)	(47)	(46)
Cyst	1 [3.0]			1 [3.0]
Pituitary Gland	(50)	(49)	(49)	(50)
Pars Distalis, Cyst	4 [3.0]	2 [3.0]	4 [3.0]	3 [3.0]
Pars Distalis, Hyperplasia, Focal	1 [1.0]			1 [1.0]
Thyroid Gland	(50)	(50)	(50)	(50)
Follicle, Cyst				1 [3.0]
Follicle, Degeneration, Focal	12 [2.0]	8 [1.4]	9 [1.9]	9 [1.9]
Follicular Cell, Hyperplasia				2 [1.0]
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Epididymis	(50)	(50)	(50)	(50)
Granuloma Sperm	1 [3.0]			
Spermatocele	1 [3.0]			
Preputial Gland	(50)	(50)	(50)	(50)
Cyst	1 [3.0]	2 [3.0]		4 [3.0]
Inflammation, Chronic	7 [2.1]	4 [2.0]	3 [2.0]	7 [2.0]
Prostate	(50)	(50)	(50)	(50)
Inflammation, Chronic	3 [2.3]			
Seminal Vesicle	(50)	(50)	(50)	(50)
Degeneration		1 [4.0]		
Inflammation, Chronic	1 [3.0]			1 [2.0]
Testes	(50)	(50)	(50)	(50)
Germinal Epithelium, Atrophy	2 [1.5]	2 [2.0]	4 [2.3]	2 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Androstenedione

Time Report Requested: 12:55:58

Route: GAVAGE

CAS Number: 63-05-8

First Dose M/F: 12/16/02 / 12/16/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Atrophy			1 [3.0]	
Hyperplasia	19 [2.4]	30 [2.6]	23 [3.0]	30 [2.5]
Infiltration Cellular, Histiocyte			1 [3.0]	
Myelofibrosis			1 [2.0]	
Lymph Node	(2)	(1)	(1)	(4)
Iliac, Hyperplasia, Lymphoid			1 [3.0]	
Lymph Node, Mandibular	(47)	(47)	(47)	(47)
Atrophy			3 [2.3]	
Hematopoietic Cell Proliferation	1 [1.0]	1 [2.0]		
Hyperplasia, Lymphoid	5 [2.2]	5 [3.0]	3 [2.3]	3 [2.7]
Pigmentation	1 [2.0]			1 [3.0]
Lymph Node, Mesenteric	(49)	(49)	(49)	(45)
Angiectasis			2 [2.5]	
Atrophy		4 [2.3]	6 [2.5]	
Hematopoietic Cell Proliferation	4 [2.3]	4 [2.0]	6 [2.3]	2 [2.0]
Hemorrhage	4 [2.8]	4 [1.8]	7 [1.7]	2 [1.5]
Hyperplasia, Lymphoid	2 [2.5]	5 [2.8]	1 [3.0]	4 [2.3]
Spleen	(50)	(50)	(50)	(50)
Accessory Spleen	1	1		
Fibrosis	1 [2.0]			
Hematopoietic Cell Proliferation	23 [3.0]	25 [2.8]	28 [3.0]	28 [2.9]
Necrosis				1 [4.0]
Lymphoid Follicle, Atrophy		1 [3.0]	4 [3.0]	
Lymphoid Follicle, Hyperplasia		1 [2.0]	1 [2.0]	1 [2.0]
Thymus	(45)	(46)	(42)	(45)
Atrophy	4 [3.3]	5 [2.4]	13 [3.1]	8 [3.0]
Cyst		2 [3.0]		5 [3.0]
Hyperplasia, Lymphoid		2 [4.0]	1 [4.0]	
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion			1	
Edema	1 [4.0]	1 [3.0]	1 [2.0]	
Hemorrhage	1 [3.0]			
Hyperkeratosis	1 [2.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Androstenedione

Time Report Requested: 12:55:58

Route: GAVAGE

CAS Number: 63-05-8

First Dose M/F: 12/16/02 / 12/16/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Ulcer Epidermis, Hyperplasia	1 [2.0]	2 [3.5] 1 [3.0]		1 [4.0] 1 [3.0]
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Cranium, Osteopetrosis			1 [3.0]	2 [1.5]
Skeletal Muscle	(1)	(1)	(2)	(1)
Atrophy			1 [1.0]	1 [2.0]
NERVOUS SYSTEM				
Brain	(50)	(50)	(49)	(50)
Cyst Epithelial Inclusion		1		
Hemorrhage	1 [3.0]	1 [4.0]		
Peripheral Nerve	(1)	(1)	(4)	(3)
Atrophy		1 [2.0]	2 [1.0]	1 [2.0]
Spinal Cord	(1)	(1)	(4)	(3)
Necrosis			1 [3.0]	
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Angiectasis			1 [2.0]	
Foreign Body			1	
Hemorrhage	4 [1.8]	1 [1.0]	1 [2.0]	2 [2.0]
Infiltration Cellular, Histiocyte	10 [3.4]	5 [2.6]	5 [3.4]	11 [3.0]
Infiltration Cellular, Lymphocyte				1 [2.0]
Inflammation, Chronic	1 [2.0]			
Metaplasia, Osseous		1 [1.0]		
Thrombosis	2 [1.5]		1 [4.0]	
Alveolar Epithelium, Hyperplasia	4 [1.8]	2 [1.5]	2 [1.0]	3 [1.3]
Bronchus, Hyperplasia				1 [4.0]
Nose	(50)	(49)	(49)	(50)
Foreign Body	4			
Hemorrhage		1 [3.0]		
Inflammation, Chronic	5 [1.4]	4 [1.3]	4 [1.3]	3 [1.7]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Androstenedione

Time Report Requested: 12:55:58

Route: GAVAGE

CAS Number: 63-05-8

First Dose M/F: 12/16/02 / 12/16/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Atrophy		1 [4.0]		
Cataract	1 [3.0]	1 [2.0]		1 [3.0]
Hemorrhage	1 [2.0]			
Inflammation, Chronic	3 [2.0]	1 [2.0]	2 [2.5]	
Cornea, Hyperplasia	1 [2.0]	1 [2.0]		1 [1.0]
Retina, Degeneration	1 [2.0]			1 [3.0]
Harderian Gland	(50)	(50)	(50)	(50)
Cyst			1 [4.0]	
Lacrimal Gland	(0)	(1)	(0)	(0)
Duct, Inflammation, Suppurative		1 [4.0]		
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Cyst	9 [3.0]	16 [3.0]	9 [3.0]	13 [3.0]
Hydronephrosis	1 [2.0]	2 [1.5]	1 [2.0]	2 [2.0]
Infarct	4 [1.5]	2 [1.0]	1 [1.0]	5 [2.2]
Infiltration Cellular, Lymphocyte	5 [2.6]	2 [2.0]	4 [2.8]	5 [3.0]
Inflammation, Suppurative			1 [4.0]	
Metaplasia, Osseous	4 [1.8]	2 [2.5]	5 [2.0]	4 [1.8]
Mineralization			2 [3.0]	
Nephropathy	38 [1.3]	45 [1.2]	38 [1.3]	44 [1.4]
Renal Tubule, Accumulation, Hyaline Droplet			1 [3.0]	
Renal Tubule, Dilatation, Diffuse			1 [2.0]	
Renal Tubule, Hyperplasia	7 [1.1]	6 [1.0]	6 [1.0]	2 [1.0]
Renal Tubule, Pigmentation	1 [4.0]	3 [2.3]	6 [3.0]	3 [3.0]
Transitional Epithelium, Hyperplasia		1 [2.0]		
Urinary Bladder	(50)	(50)	(50)	(50)
Edema	1 [3.0]	1 [3.0]		
Transitional Epithelium, Hyperplasia		1 [2.0]	2 [2.5]	

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Androstenedione

Time Report Requested: 12:55:58

Route: GAVAGE

CAS Number: 63-05-8

First Dose M/F: 12/16/02 / 12/16/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Accidently Killed	2		1	1
Moribund Sacrifice	6	2	3	3
Natural Death	7	8	6	6
Survivors				
Natural Death	1		1	
Terminal Sacrifice	34	40	39	40
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(49)	(50)
Gallbladder	(44)	(45)	(42)	(48)
Cyst				1 [3.0]
Intestine Large, Cecum	(49)	(50)	(50)	(49)
Edema		1 [2.0]		
Intestine Small, Duodenum	(47)	(46)	(46)	(49)
Metaplasia	1 [2.0]			
Epithelium, Hyperplasia			1 [2.0]	
Intestine Small, Ileum	(46)	(48)	(49)	(50)
Epithelium, Hyperplasia		1 [2.0]		
Intestine Small, Jejunum	(46)	(48)	(49)	(50)
Hyperplasia, Lymphoid		1 [3.0]		
Liver	(50)	(50)	(50)	(50)
Angiectasis	1 [3.0]	1 [4.0]	1 [4.0]	
Basophilic Focus		4	3	
Clear Cell Focus	2	1	1	3
Eosinophilic Focus	9	8	11	11
Hematopoietic Cell Proliferation	6 [2.2]	2 [2.5]	4 [2.3]	3 [2.3]
Hemorrhage		1 [3.0]		
Infiltration Cellular, Lymphocyte	1 [2.0]	2 [2.5]	2 [2.5]	
Infiltration Cellular, Mixed Cell	2 [2.5]	4 [2.5]	2 [2.0]	
Mixed Cell Focus	2	5	7	15
Necrosis, Focal	2 [1.5]	5 [2.0]	2 [1.0]	2 [2.5]
Tension Lipidosis	1		1	2

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Androstenedione

Time Report Requested: 12:55:58

Route: GAVAGE

CAS Number: 63-05-8

First Dose M/F: 12/16/02 / 12/16/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Centrilobular, Necrosis Hepatocyte, Hypertrophy	1 [4.0]	1 [4.0]	1 [2.0]	1 [2.0]
Hepatocyte, Vacuolization Cytoplasmic	6 [2.7]	3 [2.3]	9 [2.1]	22 [2.6]
Kupffer Cell, Hyperplasia		1 [3.0]	1 [3.0]	
Kupffer Cell, Pigmentation	2 [2.5]			
Oval Cell, Hyperplasia				1 [2.0]
Mesentery	(7)	(9)	(14)	(8)
Fat, Necrosis	7 [3.7]	6 [3.2]	13 [3.2]	8 [2.8]
Oral Mucosa	(0)	(0)	(0)	(1)
Pancreas	(49)	(50)	(50)	(49)
Atrophy	1 [2.0]		2 [3.5]	4 [2.0]
Cyst		1 [3.0]	3 [3.0]	1 [3.0]
Infiltration Cellular, Lymphocyte	1 [3.0]			
Acinus, Cytoplasmic Alteration	1 [3.0]	1 [3.0]	3 [3.0]	1 [3.0]
Salivary Glands	(49)	(49)	(49)	(50)
Atrophy	1 [2.0]			
Infiltration Cellular, Lymphocyte	10 [2.9]	12 [2.7]	2 [3.0]	7 [2.4]
Submandibular Gland, Cytoplasmic Alteration		17 [1.2]	40 [1.4]	45 [2.5]
Stomach, Forestomach	(50)	(50)	(50)	(50)
Diverticulum		1		
Metaplasia, Hepatocyte		1 [2.0]		
Ulcer	1 [2.0]			1 [2.0]
Epithelium, Hyperplasia		1 [3.0]	1 [1.0]	3 [2.0]
Stomach, Glandular	(50)	(50)	(50)	(50)
Cyst	2 [3.0]			
Erosion	1 [2.0]	1 [2.0]		
Metaplasia, Hepatocyte				1 [3.0]
Mineralization			1 [2.0]	
Ulcer	1 [2.0]			
Epithelium, Hyperplasia	1 [2.0]			1 [3.0]
CARDIOVASCULAR SYSTEM				
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	1 [1.0]	2 [2.0]		2 [1.0]
Inflammation, Acute	1 [2.0]			
Inflammation, Chronic				1 [2.0]
Mineralization	1 [3.0]	1 [1.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Androstenedione

Time Report Requested: 12:55:58

Route: GAVAGE

CAS Number: 63-05-8

First Dose M/F: 12/16/02 / 12/16/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Thrombosis			1 [2.0]	
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Accessory Adrenal Cortical Nodule	3 [3.0]	7 [3.0]	5 [3.0]	3 [3.0]
Hyperplasia, Focal	1 [2.0]	1 [1.0]		1 [1.0]
Hypertrophy, Focal		1 [2.0]		1 [1.0]
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	4 [1.5]	1 [1.0]	1 [2.0]	1 [2.0]
Islets, Pancreatic	(49)	(50)	(49)	(48)
Hyperplasia	1 [2.0]	1 [3.0]	1 [3.0]	
Parathyroid Gland	(48)	(49)	(45)	(50)
Cyst		1 [3.0]	1 [3.0]	2 [3.0]
Pituitary Gland	(49)	(47)	(50)	(50)
Pars Distalis, Angiectasis	1 [2.0]	1 [2.0]	2 [2.5]	2 [1.5]
Pars Distalis, Cyst	1 [3.0]	1 [3.0]		1 [3.0]
Pars Distalis, Hyperplasia		1 [3.0]	1 [4.0]	
Pars Distalis, Hyperplasia, Focal	5 [2.0]	8 [1.3]	7 [1.7]	7 [1.7]
Thyroid Gland	(50)	(50)	(48)	(50)
Follicle, Cyst			1 [3.0]	
Follicle, Degeneration, Focal	26 [2.1]	18 [1.8]	20 [2.0]	19 [2.0]
Follicular Cell, Hyperplasia		1 [1.0]	2 [1.5]	1 [1.0]
GENERAL BODY SYSTEM				
Tissue NOS	(1)	(0)	(0)	(1)
GENITAL SYSTEM				
Clitoral Gland	(47)	(47)	(49)	(50)
Hyperplasia		2 [1.0]	13 [1.9]	41 [2.0]
Duct, Dilatation		2 [1.0]	17 [1.4]	49 [2.6]
Ovary	(49)	(50)	(49)	(48)
Angiectasis		4 [2.3]	2 [3.0]	1 [3.0]
Cyst	11 [3.0]	14 [3.0]	10 [3.0]	15 [2.9]
Hemorrhage	4 [2.8]		1 [2.0]	6 [2.2]
Corpus Luteum, Hyperplasia		1 [2.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Androstenedione

Time Report Requested: 12:55:58

Route: GAVAGE

CAS Number: 63-05-8

First Dose M/F: 12/16/02 / 12/16/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Interstitial Cell, Hyperplasia	1 [3.0]		2 [2.0]	
Uterus	(50)	(50)	(50)	(50)
Angiectasis	1 [3.0]		2 [2.0]	4 [2.3]
Hyperplasia, Cystic	44 [3.0]	42 [3.2]	42 [3.1]	36 [2.4]
Endometrium, Dysplasia			1 [2.0]	
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(49)	(50)	(50)
Hyperplasia	14 [3.2]	18 [2.8]	23 [2.7]	11 [2.2]
Infiltration Cellular, Histiocyte			1 [3.0]	
Lymph Node	(10)	(5)	(4)	(1)
Iliac, Hematopoietic Cell Proliferation		2 [3.0]		
Iliac, Hemorrhage	1 [4.0]	1 [2.0]		
Iliac, Hyperplasia, Lymphoid		1 [2.0]		
Inguinal, Hyperplasia, Lymphoid	1 [2.0]			
Mediastinal, Hyperplasia, Lymphoid			1 [2.0]	
Renal, Hematopoietic Cell Proliferation		1 [2.0]		
Renal, Hyperplasia, Lymphoid				1 [3.0]
Lymph Node, Mandibular	(46)	(49)	(47)	(49)
Atrophy			1 [2.0]	
Hematopoietic Cell Proliferation		1 [3.0]		1 [2.0]
Hemorrhage			2 [1.5]	
Hyperplasia, Lymphoid	4 [2.5]	3 [2.7]	4 [2.8]	2 [2.5]
Pigmentation	4 [3.0]	4 [2.8]	4 [3.0]	3 [2.7]
Lymph Node, Mesenteric	(50)	(50)	(46)	(48)
Atrophy	1 [2.0]	1 [3.0]	2 [2.5]	
Hematopoietic Cell Proliferation			1 [2.0]	
Hemorrhage	1 [4.0]	4 [3.5]	2 [2.5]	1 [4.0]
Hyperplasia, Lymphoid		3 [2.3]	5 [2.2]	1 [2.0]
Spleen	(50)	(50)	(50)	(50)
Accessory Spleen	1			1
Hematopoietic Cell Proliferation	28 [2.6]	29 [2.5]	32 [2.5]	22 [2.4]
Necrosis	1 [3.0]	1 [4.0]		
Lymphoid Follicle, Atrophy			1 [3.0]	2 [2.5]
Lymphoid Follicle, Hyperplasia	7 [2.4]	6 [2.3]	15 [2.5]	8 [2.1]
Red Pulp, Hyperplasia				1 [3.0]
Thymus	(47)	(46)	(46)	(46)
Atrophy	2 [3.0]	3 [2.7]	4 [2.8]	3 [2.3]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Androstenedione

Time Report Requested: 12:55:58

Route: GAVAGE

CAS Number: 63-05-8

First Dose M/F: 12/16/02 / 12/16/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Cyst Hyperplasia, Lymphoid	1 [3.0]	2 [2.0]		
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Hyperplasia	4 [2.0]	3 [2.3]	5 [2.4]	2 [3.5]
Skin	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion			1	
Edema	1 [3.0]	1 [3.0]		
Inflammation, Chronic	1 [3.0]			
Metaplasia, Osseous	1 [3.0]			
Ulcer	2 [4.0]		2 [3.5]	
Epidermis, Hyperplasia	1 [3.0]			
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Fibrosis	3 [2.3]	4 [2.5]	4 [2.3]	5 [2.2]
Hyperostosis	1 [2.0]			
Skeletal Muscle	(4)	(0)	(4)	(2)
Atrophy			1 [1.0]	
Hemorrhage				1 [2.0]
NERVOUS SYSTEM				
Brain	(50)	(49)	(50)	(50)
Compression			1 [3.0]	2 [3.5]
Cyst Epithelial Inclusion	1			
Gliosis	1 [2.0]			1 [2.0]
Hydrocephalus				1 [2.0]
Peripheral Nerve	(2)	(1)	(3)	(1)
Atrophy	2 [1.5]		2 [2.5]	1 [3.0]
Inflammation, Chronic Active				1 [3.0]
Spinal Cord	(2)	(1)	(4)	(1)
RESPIRATORY SYSTEM				

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Androstenedione

Time Report Requested: 12:55:58

Route: GAVAGE

CAS Number: 63-05-8

First Dose M/F: 12/16/02 / 12/16/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Lung	(50)	(50)	(50)	(50)
Hemorrhage	2 [2.5]	3 [1.3]	3 [2.0]	7 [1.7]
Infiltration Cellular, Histiocyte	2 [3.5]	1 [4.0]	1 [1.0]	4 [3.8]
Infiltration Cellular, Lymphocyte	1 [2.0]	1 [3.0]		
Metaplasia, Osseous		1 [1.0]		
Mineralization			1 [3.0]	
Thrombosis			1 [2.0]	
Alveolar Epithelium, Hyperplasia	1 [1.0]		1 [1.0]	
Nose	(50)	(49)	(50)	(50)
Inflammation, Chronic	1 [2.0]	3 [1.3]		4 [1.5]
Trachea	(50)	(50)	(48)	(50)
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Cataract			2 [2.5]	
Inflammation, Chronic	2 [1.5]		2 [2.0]	1 [1.0]
Cornea, Hyperplasia	2 [1.5]		1 [2.0]	
Harderian Gland	(50)	(50)	(50)	(50)
Hyperplasia, Focal	1 [2.0]	2 [2.5]	1 [2.0]	1 [2.0]
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Cyst		1 [3.0]	1 [3.0]	1 [3.0]
Glomerulosclerosis			3 [2.7]	
Hydronephrosis				1 [2.0]
Infarct	4 [2.5]	3 [2.7]	1 [1.0]	
Infiltration Cellular, Lymphocyte	4 [2.5]	4 [2.8]	2 [2.5]	3 [2.0]
Inflammation, Suppurative	2 [2.5]		1 [1.0]	
Metaplasia, Osseous	1 [1.0]	2 [3.0]		3 [1.3]
Nephropathy	13 [1.2]	11 [1.2]	13 [1.2]	14 [1.1]
Glomerulus, Metaplasia	2 [1.5]	1 [2.0]	5 [1.0]	27 [2.0]
Renal Tubule, Accumulation, Hyaline Droplet	1 [3.0]	3 [2.7]		
Renal Tubule, Hyperplasia		1 [1.0]		1 [1.0]
Renal Tubule, Pigmentation		1 [1.0]		1 [1.0]
Transitional Epithelium, Hyperplasia			1 [2.0]	
Urinary Bladder	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

Androstenedione

Time Report Requested: 12:55:58

Route: GAVAGE

CAS Number: 63-05-8

First Dose M/F: 12/16/02 / 12/16/02

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Infiltration Cellular, Lymphocyte	1 [2.0]	4 [2.8]	2 [3.0]	
Inflammation, Chronic	1 [3.0]			
Transitional Epithelium, Hyperplasia	1 [2.0]		2 [2.5]	1 [3.0]

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion
 b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)